Please assess the completion status of the following clinical trial:

Trial Title: Saxagliptin Triple Oral Therapy

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Written Informed Consent~* Males or females with type 2 diabetes with inadequate glycaemic control (HbA1c \> or = 7% and \< or = 10%) despite being on combination of metformin and sulfonylurea for at least 8 weeks prior to Visit 1~* BMI \< or = 40 kg/m2~Exclusion Criteria:~* Symptoms of poorly controlled diabetes including but not limited to marked polyuria and marked polydipsia with \> 10% weight loss in 3 months prior to entry, or other signs and symptoms~* History of diabetic ketoacidosis or hyperosmolar non-ketotic coma~* Current or prior use within 3 months of Visit 1 of insulin, DDP4 inhibitor, GLP-1 analogues, and/or other oral anti-diabetic agents (other than metformin or sulfonylurea)~* Treatment with CYP3A4 inducers and/or potent CYP3A4/5 inhibitor~* Estimated CrCl \< 60 ml/min at Visit 2~* CHF (NYHA class III or IV) and/or LVEF \<40%~* Active liver disease and/or significant abnormal liver function defined as AST and/or ALT \> 3 x ULN and/or bilirubin \> 2.0 mg/dL at Visit 2.~* Creatine kinase \> or = 10 x ULN at Visit 2

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Saxagliptin 5 mg once daily (Type: EXPERIMENTAL): None
- Placebo once daily (Type: PLACEBO_COMPARATOR): None

Based on this trial design, predict the completion outcome and termination type (if applicable).